Beyond Air (XAIR) 2nd Annual Lytham Partners Healthcare Investor Summit summary

Product overview and differentiation

• Nitric oxide is a natural pulmonary vasodilator used to treat hypoxic respiratory failure in newborns and right ventricular dysfunction post-cardiac surgery.

• The system generates nitric oxide from room air, eliminating the need for heavy cylinders or toxic chemicals, making it safer, greener, and more cost-effective.

• The device is easier to use, reduces hospital logistics, and offers significant cost and space savings.

Market adoption and strategy

• Initial U.S. launch faced challenges due to pandemic-related ventilator upgrades and regulatory delays, delaying a competitive product until mid-2024.

• First-generation device lacked transport capability, limiting adoption in hospitals needing inter-hospital transport.

• Second-generation device, pending FDA approval by year-end, will be smaller, user-friendly, and suitable for transport, aiming to capture majority U.S. market share.

• International expansion began less than nine months ago, with distribution partners in 40 countries and expectations for significant overseas impact in 12–24 months.

Global market potential

• International pricing is close to U.S. levels, but global volume is much higher, especially in Europe and Asia.

• The ex-U.S. market is expected to double the U.S. market in dollar value over the next five to seven years.

• The system's ease of use and lack of cylinder dependency enable access to remote areas previously underserved.

• Distribution partners are key to rapid international growth, with revenues expected to accelerate in 2026 and significantly impact financials in 2027.